— Know what they know.
Not Investment Advice
Also trades as: FRE.DE (XETRA) · $vol 53M · FSNUY (OTC) · $vol 1M · FRE.SW (SIX) · $vol 0M

FSNUF OTC

Fresenius SE & Co. KGaA
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: -2.8% 1Y: +17.6% 3Y: +132.6% 5Y: +40.9%
$57.00
+2.65 (+4.88%)
 
OTC · Healthcare · Medical - Care Facilities · Alpha Radar Buy · Power 57 · $32.1B mcap · 411M float · 0.0000% daily turnover · Short 100% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$32.1B
52W Range46.21-58.16
Volume165
Avg Volume141
Beta0.82
Dividend$1.22
Analyst Ratings
1 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOMichael Sen
Employees175,202
SectorHealthcare
IndustryMedical - Care Facilities
IPO Date2012-03-14
Else-Kroener-Strasse 1
Bad Homburg vor der Höhe, HE 61352
DE
49 6172 608 2487
About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA is a diversified healthcare enterprise delivering a broad spectrum of products and services across multiple sectors, including dialysis, hospital operations, and outpatient medical treatment. Its operations are structured into four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care specializes in supporting individuals suffering from chronic kidney disease, supplying essential products like dialyzers, hemodialysis equipment, and associated disposable items, alongside comprehensive dialysis services. Fresenius Kabi focuses on the therapeutic management and care of acutely and chronically ill patients. Its portfolio encompasses a wide range of offerings, including intravenous generic pharmaceuticals for areas like oncology, pain management, anesthesia, infection control, and critical care. It also provides parenteral and enteral nutritional solutions, infusion fluids, blood volume expanders, and biosimilar drugs targeting autoimmune and oncological conditions. Furthermore, the segment supplies medical devices and consumables vital for administering IV medications, infusion therapies, and clinical nutrition, along with transfusion products for blood component collection and various bodily treatments. Fresenius Helios manages a substantial network of healthcare facilities. In Germany, it operates 90 hospitals, around 130 outpatient clinics, and six prevention centers. Its Spanish presence includes 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers. Additionally, this segment extends its services to fertility treatment, operating 33 dedicated clinics and 39 supplementary locations spanning ten countries across three continents. Fresenius Vamed is dedicated to project management and service provision for hospitals and other healthcare infrastructure. Its comprehensive offerings range from project conception, detailed planning, and complete turnkey construction to ongoing maintenance, technical oversight, and operational administration. Originally established in 1912, the company was previously known as Fresenius SE before adopting its current name, Fresenius SE & Co. KGaA, in January 2011. Its global headquarters are situated in Bad Homburg vor der Höhe, Germany.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms